NasdaqGS - Nasdaq Real Time Price USD

Rallybio Corporation (RLYB)

0.2970

+0.0014

+(0.47%)

At close: 4:00:00 PM EDT

0.3015

+0.00

+(1.52%)

After hours: 6:08:36 PM EDT

RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks

Rallybio halts development of RLYB212 in a phase II study for the prevention of fetal and neonatal alloimmune thrombocytopenia. Stock falls.

Zacks 15 days ago

RLYB
+0.47%
Rallybio drops drug for rare maternal disorder following Phase II fail

Rallybio will prioritise another candidate that is being investigated in complement-driven diseases.

Clinical Trials Arena 15 days ago

RLYB
+0.47%
GLDAF
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

NEW HAVEN, Conn., April 08, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the discontinuation of the RLYB212 program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The Company’s decision to discontinue RLYB212 development was based on pharmacokinetic (PK) data from the Phase 2 clinical trial demonstrating the

Business Wire 16 days ago

RLYB
+0.47%
Rallybio discontinues lead drug for rare maternal disorder

The company has decided to switch gears following disappointing data for a monoclonal antibody targeting a rare maternal blood disorder.

BioPharma Dive 16 days ago

RLYB
+0.47%
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

NEW HAVEN, Conn., March 13, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided an update on recent company developments.

Business Wire last month

RLYB
+0.47%
Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. last month

RLYB
+0.47%
Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

NEW HAVEN, Conn., February 25, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will present a corporate overview at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at 1:10 p.m. EST in Boston, MA.

Business Wire last month

RLYB
+0.47%
Rallybio doses first subject in Phase II trial of treatment for FNAIT in Europe

Initial data from the second trimester are anticipated by the second quarter of this year.

Clinical Trials Arena 2 months ago

RLYB
+0.47%
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

NEW HAVEN, Conn., February 11, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that the first participant has been dosed in the Phase 2 trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). Pharmacokinetic (PK) and safety data from the second trime

Business Wire 2 months ago

RLYB
+0.47%
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

NEW HAVEN, Conn., January 10, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today highlighted its 2024 accomplishments and announced its anticipated key milestones for 2025.

Business Wire 3 months ago

RLYB
+0.47%
US Penny Stocks To Consider In December 2024

As the U.S. stock market experiences a pullback from recent record highs, investors are closely monitoring economic indicators and potential interest rate changes. For those willing to explore beyond well-known large-cap stocks, penny stocks can offer intriguing opportunities despite their historical connotations. While often associated with smaller or newer companies, penny stocks can present a blend of affordability and growth potential when backed by strong financials.

Simply Wall St. 4 months ago

RLYB
+0.47%
PERF

PERF-WS
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

NEW HAVEN, Conn., December 10, 2024--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the presentation of two posters highlighting promising preclinical data for pipeline candidates RLYB212 and RLYB332 at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7–10, 2024 in San Diego, California.

Business Wire 4 months ago

RLYB
+0.47%
Rallybio price target lowered to $7 from $8 at JMP Securities

JMP Securities analyst Jonathan Wolleben lowered the firm’s price target on Rallybio (RLYB) to $7 from $8 and keeps an Outperform rating on the shares as part of a broader note on Biotechnology. The firm highlighted key upcoming catalysts for its coverage universe over the next 12 months, ahead of what is shaping up to be a “busy” 2025, and noted that it still has several events expected between now and the end of the year which could provide a reason for “cheer” this holiday season. Published f

TipRanks 4 months ago

RLYB
+0.47%
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

NEW HAVEN, Conn., December 02, 2024--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced results of new biomarker characterization analyses and data from the recently completed manufacturing process enhancements for RLYB116, the Company’s innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of pa

Business Wire 4 months ago

RLYB
+0.47%
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

NEW HAVEN, Conn., November 27, 2024--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the publication of a manuscript titled, "Informing Pregnancy Dose via Target-Mediated Drug Disposition Modeling and Simulations for a Recombinant Human Monoclonal Antibody," in a special pregnancy themed issue of Clinical Pharmacology and Therapeutics: Pharmacomet

Business Wire 4 months ago

RLYB
+0.47%
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

NEW HAVEN, Conn., November 26, 2024--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET in Coral Gables, FL.

Business Wire 4 months ago

RLYB
+0.47%
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

NEW HAVEN, Conn., November 25, 2024--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that the Company will host a webcast to provide a program update on RLYB116, its innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of patients with complement-mediated diseases. The webcast will take place

Business Wire 4 months ago

RLYB
+0.47%
Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women

The trial is currently in the screening phase to identify the first subject.

Clinical Trials Arena 4 months ago

RLYB
+0.47%
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

NEW HAVEN, Conn., November 21, 2024--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of its Phase 2 clinical trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). Screening is now underway to identify the first (sentinel) pregnant woman fo

Business Wire 4 months ago

RLYB
+0.47%
3 US Penny Stocks With Market Caps Over $40M To Consider

As the U.S. stock market takes a breather following a post-election rally, investors are keenly observing opportunities that might arise in different sectors. Penny stocks, despite their somewhat outdated name, remain relevant as they often represent smaller or newer companies with potential for growth. With strong financial foundations and solid fundamentals, these stocks can offer valuable opportunities for those willing to explore beyond the well-trodden paths of larger firms.

Simply Wall St. 5 months ago

IKNA
0.00%
MNOV

RLYB
+0.47%

Performance Overview

Return	RLYB	S&P 500 (^GSPC)
YTD	-69.06%	-6.75%
1-Year	-81.20%	+8.15%
3-Year	-97.06%	+28.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Rallybio Corporation (RLYB)

RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks

Rallybio drops drug for rare maternal disorder following Phase II fail

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Rallybio discontinues lead drug for rare maternal disorder

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Rallybio doses first subject in Phase II trial of treatment for FNAIT in Europe

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

US Penny Stocks To Consider In December 2024

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Rallybio price target lowered to $7 from $8 at JMP Securities

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

3 US Penny Stocks With Market Caps Over $40M To Consider

Performance Overview